Crizotinib, a Novel Inhibitor of ALK, Induces Apoptosis and Down Regulation of pSTAT3 in ALK+ Anaplastic Large Cell Lymphoma

被引：0
|
作者：
Hamedani, F. Saei
Mo, Z.
Amin, H. M.
Cervania, M. A.
Alkan, S.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MODERN PATHOLOGY | 2013年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1502
引用
收藏
页码：359A / 359A
页数：1
相关论文
共 50 条
  • [21] Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma
    Molavi, Ommoleila
    Samadi, Nasser
    Wu, Chengsheng
    Lavasanifar, Afsaneh
    Lai, Raymond
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1154 - 1162
  • [22] Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma
    Wang, Leiming
    Yao, Shuyang
    Teng, Lianghong
    Zhang, Weiwei
    Chen, Li
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : E44 - E46
  • [23] NPM/ALK oncogene induces constitutive activation of STAT3 in ALK+ T-cell lymphoma
    Zhang, Q
    Raghunath, PN
    Xue, L
    Carpentieri, DF
    Morris, S
    Skorski, T
    Wasik, MA
    FASEB JOURNAL, 2000, 14 (04): : A448 - A448
  • [24] ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation
    Shin, Saeam
    Kim, Juwon
    Yoon, Sun Och
    Kim, Yu Ri
    Lee, Kyung-A.
    LEUKEMIA RESEARCH, 2012, 36 (07) : E143 - E145
  • [25] Refractory or relapsed ALK-positive anaplastic T large cell lymphoma treated with crizotinib
    Miaomiao, L.
    Zhang, M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1758 - 1758
  • [26] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Ganesan, Prasanth
    Joshua, Thanda
    Sundersingh, Shirley
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 353 - 354
  • [27] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Prasanth Ganesan
    Thanda Joshua
    Shirley Sundersingh
    Tenali Gnana Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 353 - 354
  • [28] ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population
    Ling Huang
    Fen Zhang
    Jialong Zeng
    Hanguo Guo
    Sichu Liu
    Xiaojuan Wei
    Feili Chen
    Xinmiao Jiang
    Zhanli Liang
    Yanhui Liu
    Wenyu Li
    Annals of Hematology, 2018, 97 : 149 - 159
  • [29] Immune response to ALK in ALK-positive anaplastic large cell lymphoma
    Woessmann, W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 23 - 24
  • [30] A novel role of IL-22R1 as a possible driver of inflammation in ALK+ anaplastic large cell lymphoma
    Savan, Ram
    Reynolds, Della A.
    McFarland, Adelle P.
    Feigenbaum, Lionel
    Ramakrishnan, Karthika
    Shirota, Hidekazu
    Klinman, Dennis M.
    Dunleavy, Kieron
    Pittaluga, Stefania
    Anderson, Stephen K.
    Donnelly, Raymond P.
    Wilson, Wyndham H.
    Young, Howard
    CYTOKINE, 2010, 52 (1-2) : 69 - 69
12345